SIGA Technologies

From SourceWatch
Jump to navigation Jump to search

SIGA "designs and develops novel countermeasures to prevent and treat serious infectious diseases, with an emphasis on biological warfare defense. SIGA’s leading program is ST-246®, an oral therapeutic agent active against orthopoxviruses including smallpox. Additional programs target arenaviruses such as Lassa fever, filoviruses such as Ebola and Marburg, flaviviruses such as Dengue fever, and other category A diseases." [1]

Board

Accessed May 2010: [2]

Contact

URL: http://www.siga.com

Resources and articles

Related Sourcewatch

References

  1. About, SIGA Technologies, accessed May 5, 2010.
  2. Directors, SIGA Technologies, accessed May 5, 2010.